| Literature DB >> 35891517 |
Jin-Hui Zhu1, Gaurav Rawal1, Ethan Aljets1, Wannarat Yim-Im1, Yong-Le Yang2, Yao-Wei Huang2, Karen Krueger1, Phillip Gauger1, Rodger Main1, Jianqiang Zhang1.
Abstract
A PEDV/PDCoV/TGEV/SADS-CoV/XIPC 5-plex real-time RT-PCR was developed and validated for the simultaneous detection and differentiation of four swine enteric coronaviruses (PEDV, PDCoV, TGEV and SADS-CoV) in one PCR reaction (XIPC serves as an exogenous internal positive control). The 5-plex PCR had excellent analytical specificity, analytical sensitivity, and repeatability based on the testing of various viral and bacterial pathogens, serial dilutions of virus isolates, and in vitro transcribed RNAs. The 5-plex PCR had comparable diagnostic performance to a commercial PEDV/TGEV/PDCoV reference PCR, based on the testing of 219 clinical samples. Subsequently, 1807 clinical samples collected from various U.S. states during 2019-2021 were tested by the 5-plex PCR to investigate the presence of SADS-CoV in U.S. swine and the frequency of detecting swine enteric CoVs. All 1807 samples tested negative for SADS-CoV. Among the samples positive for swine enteric CoVs, there was a low frequency of detecting TGEV, an intermediate frequency of detecting PDCoV, and a high frequency of detecting PEDV. Although there is no evidence of SADS-CoV presence in the U.S. at present, the availability of the 5-plex PCR will enable us to conduct ongoing surveillance to detect and differentiate these viruses in swine samples and other host species samples as some of these coronaviruses can cause cross-species infection.Entities:
Keywords: 5-plex real-time RT-PCR; PDCoV; PEDV; SADS-CoV; TGEV; swine enteric coronavirus
Mesh:
Year: 2022 PMID: 35891517 PMCID: PMC9324624 DOI: 10.3390/v14071536
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.818
Sequences of primers and probes used in this study.
| Assay | Primer/Probe | Sequence (5′–3′) | Target | Amplicon | Reference |
|---|---|---|---|---|---|
|
| |||||
| Assay 1 | SADS-N-F1 | CTGACTGTTGTTGAGGTTAC | N | 155 bp | Zhou L et al., J Virol Methods. 2018, 255:66–70 [ |
| SADS-N-R1 | TCTGCCAAAGCTTGTTTAAC | N | |||
| SADS-N-Prb1 | FAM/TCACAGTCT/ZEN/CGTTCTCGCAATCA/3IABkFQ | N | |||
| Assay 2 | SADS-N-F2 | GCACTTTTATTACCTTGGTA | N | 144 bp | Xu et al., Transbound Emerg Dis. 2019, 66:119–130 [ |
| SADS-N-R2 | GTAGCAGGTTCTTTGTTAC | N | |||
| SADS-N-Prb2 | FAM/TCCTCACGC/ZEN/AGATGCTCCTT/3IABkFQ | N | |||
| Assay 3 | SADS-N-F3 | CCAGGCCTCAAAGTGGTAAAAA | N | 85 bp | This study |
| SADS-N-R3 | TGCTTACGAGCCGGTTTAGG | N | |||
| SADS-N-Prb3 | FAM/ACCCAAACC/ZEN/AAGAAGCAGAGCTGTCTCAC/3IABkFQ | N | |||
| Assay 4 | SADS-N-F4 | TTGGCAGACTTGGGCATAGC | N | 85 bp | This study |
| SADS-N-R4 | GTGAGACAGCTCTGCTTCTTGGT | N | |||
| SADS-N-Prb4 | FAM/TCCAGGCCT/ZEN/CAAAGTGTAAAAATACACCC/3IABkFQ | N | |||
|
| |||||
| Assay 1 | PDCoV-M-RTF | CGACCACATGGCTCCAATTC | M | 70 bp | Chen et al., Virology. 2015, 482:51–59 [ |
| PDCoV-M-RTR | CAGCTCTTGCCCATGTAGCTT | M | |||
| PDCoV-M-RTP | FAM/CACACCAGT/ZEN/CGTTAAGCATGGCAAGC/3IABkFQ | M | |||
| Assay 2 | PDCoV-N-RTF | CCTACTACTGACGCGTCTTGGTT | N | 75 bp | Chen et al., Emerg Microbes Infect. 2018, 7:105 [ |
| PDCoV-N-RTR | TGCCACGAAACTGAGGATGA | N | |||
| PDCoV-N-RTP | VIC/TGCTCAAAGCTCAAAAC/MGB | N | |||
| Assay 3 | PDCoV-N-F2 | CCAGACATGTGCCTGGTGTT | N | 68 bp | This study |
| PDCoV-N-R2 | CCCYGCCTGAAAGTTGCT | N | |||
| PDCoV-N-Prb2 | ABY/ARATGCTTTTCGCTGGCCACCTTG/QSY | N | |||
|
| |||||
| Assay 1 | TGEV-N-F | TGCCATGAACAAACCAAC | N | 81 bp | Huang et al., Appl Microbiol Biotechnol. 2019, 103:4943–4952 [ |
| TGEV-N-R | GGCACTTTACCATCGAAT | N | |||
| TGEV-N-Prb | VIC/TAGCACCACGACTACCAAGC/MGB-3′ | N | |||
| Assay 2 | TGEV-S-F2 | GTGGTAATATGYTRTATGGCYTACAA | S | 101 bp | This study |
| TGEV-S-R2 | GCCAGACCATTGATTTTCAAAACT | S | |||
| TGEV-S-Prb2 | VIC/TTGCTTATTTACATGGTGCYAGT/MGB | S | |||
|
| |||||
| Assay 1 | PEDV-N306-F | CGCAAAGACTGAACCCACTAACCT | N | 198 bp | Madson et al., Vet Microbiol. 2014, 174:60–68 [ |
| PEDV-N503-R | TTGCCTCTGTTGTTACTTGGAGAT | N | |||
| PEDV-N469-Prb | FAM/TGTTGCCATTACCACGACTCCTGC/QSY | N | |||
| Assay 2 | PEDV-N1195-F | GAAGAGGCCATCTACGATGATGT | N | 75 bp | This study |
| PEDV-N1269-R | AACAGCTGTGTCCCATTCCAA | N | |||
| PEDV-N1221-Prb | JUN/TGTGCCATCTGATGTGACTCATGCCA/QSY | N | |||
|
| |||||
| PEDV-N1195-F | GAAGAGGCCATCTACGATGATGT | N | 75 bp | This study | |
| PEDV-N1269-R | AACAGCTGTGTCCCATTCCAA | N | |||
| PEDV-N1221-Prb | N | ||||
| PDCoV-N-F2 | CCAGACATGTGCCTGGTGTT | N | 68 bp | This study | |
| PDCoV-N-R2 | CCCYGCCTGAAAGTTGCT | N | |||
| PDCoV-N-Prb2 | N | ||||
| TGEV-S-F2 | GTGGTAATATGYTRTATGGCYTACAA | S | 101 bp | This study | |
| TGEV-S-R2 | GCCAGACCATTGATTTTCAAAACT | S | |||
| TGEV-S-Prb2 | S | ||||
| SADS-N-F3 | CCAGGCCTCAAAGTGGTAAAAA | N | 85 bp | This study | |
| SADS-N-R3 | TGCTTACGAGCCGGTTTAGG | N | |||
| SADS-N-Prb3 | N | ||||
Note: The singleplex PCR assays used to develop the 5-plex PCR are shown as highlighted.
Analytical specificity of various singleplex and multiplex PCRs evaluated in this study.
| Pathogens | SADS-CoV Singleplex Assay | PDCoV Singleplex Assay | TGEV Singleplex Assay | PEDV Singleplex Assay | 5-Plex PCR | Reference PEDV/ | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assay 1 | Assay 2 | Assay 3 * | Assay 4 | Assay 1 | Assay 2 | Assay 3 * | Assay 1 | Assay 2 * | Assay 1 | Assay 2 * | TGEV/PDCoV PCR | ||
| PEDV | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | 18.21 | 17.05 | 16.09 | 15.51 |
| TGEV Purdue | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | 15.00 | 17.43 | ≥40 | ≥40 | 15.87 | 15.41 |
| TGEV Miller | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | 17.23 | 19.51 | ≥40 | ≥40 | 17.53 | 16.93 |
| PDCoV | ≥40 | ≥40 | ≥40 | ≥40 | 17.93 | 17.45 | 14.01 | ≥40 | ≥40 | ≥40 | ≥40 | 16.52 | 17.35 |
| SADS-CoV RNA | 28.35 | 26.05 | 25.85 | 25.15 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | 27.56 | ≥40 |
| PRCV | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | 18.04 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
| PHEV | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
| Sparrow DCoV (17-690-7) | ≥40 | ≥40 | ≥40 | ≥40 | 34.72 | 30.91 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
| Sparrow DCoV (17-42824) | ≥40 | ≥40 | ≥40 | ≥40 | 33.08 | 27.30 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
| Porcine rotavirus (A, B, C) | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
| PCV 2 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
| Influenza A virus | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
| PPIV-1 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
| Pseudorabies virus | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
| Senecavirus A | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
| PRRSV-1 Lelystad | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
| PRRSV-2 VR-2385 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
| Bacteria ‡ | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
* Singleplex PCR assays that were selected to develop the PEDV/PDCoV/TGEV/SADS-CoV/XIPC 5-plex PCR. ‡ Bacterial pathogens for evaluating assay specificity include E. coli, Salmonella typhimurium, Clostridium difficile, Clostridium perfringens, Brachyspira hyodysenteriae, Mycoplasma hyopneumoniae, Mycoplasma hyorhinis, Mycoplasma hyosynoviae, Actinobacillus pleuropneumonia, Actinobacillus suis, Streptococcus suis, Glaesserella (Haemophilus) parasuis, Bordetella bronchiseptica, Pasteurella multocida, and Trueperella pyogenes.
Analytical sensitivity of Singleplex SADS-CoV PCR assays 2 and 3 by testing serial dilutions of a SADS-CoV cell culture isolate *.
| Dilution | Theoretical Titer (TCID50/mL) | SADS-CoV ASSAY 2 | SADS-CoV ASSAY 3 | ||||
|---|---|---|---|---|---|---|---|
| Result 1 | Result 2 | Result 3 | Result 1 | Result 2 | Result 3 | ||
| 10−2 | 5 × 105 | 20.64 | 20.68 | 20.69 | 20.76 | 20.76 | 20.69 |
| 10−3 | 5 × 104 | 24.05 | 24.03 | 24.03 | 24.01 | 23.97 | 24.13 |
| 10−4 | 5 × 103 | 27.51 | 27.47 | 27.59 | 27.44 | 27.36 | 27.42 |
| 10−5 | 5 × 102 | 31.00 | 30.99 | 31.23 | 31.10 | 31.06 | 31.24 |
| 10−6 | 5 × 101 | 34.37 | 34.25 | 33.98 | 34.78 | 34.10 | 34.95 |
| 10−7 | 5 × 100 | 38.45 | 37.24 | 38.23 | 37.45 | 37.52 | 36.58 |
| 10−8 | 5 × 10−1 | ≥40 | ≥40 | ≥40 | 37.26 | 37.15 | ≥40 |
| 10−9 | 5 × 10−2 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
* The work was conducted in Huang’s lab in China.
Analytical specificity of the 5-plex PCR examined by mixtures of different viruses.
| Sample No. | Sample Detail (Volume Mixing Ratio) | PEDV/PDCoV/TGEV/SADS-CoV/XIPC 5-Plex PCR Ct Value | ||||
|---|---|---|---|---|---|---|
| PEDV (JUN) | TGEV (VIC) | PDCoV (ABY) | SADS-CoV (FAM) | XIPC (Cy5) | ||
| Sample #1 | PEDV USA/IN19338/2013 | 15.208 | ≥40 | ≥40 | ≥40 | 31.359 |
| Sample #2 | TGEV Purdue (VR-763) | ≥40 | 13.874 | ≥40 | ≥40 | 31.658 |
| Sample #3 | PDCoV USA/IL/2014 | ≥40 | ≥40 | 16.55 | ≥40 | 31.891 |
| Sample #4 | SADS-CoV N-gene IVT RNA | ≥40 | ≥40 | ≥40 | 26.057 | 25.991 |
| Sample #5 | PEDV & TGEV (1:1) | 17.245 | 16.413 | ≥40 | ≥40 | 31.079 |
| Sample #6 | PEDV & PDCoV (1:1) | 17.375 | ≥40 | 17.332 | ≥40 | 32.060 |
| Sample #7 | TGEV & PDCoV (1:1) | ≥40 | 15.993 | 17.834 | ≥40 | 32.358 |
| Sample #8 | PEDV & SADS-CoV (1:1) | 15.646 | ≥40 | ≥40 | 26.771 | 32.073 |
| Sample #9 | TGEV & SADS-CoV (1:1) | ≥40 | 15.076 | ≥40 | 26.870 | 32.533 |
| Sample #10 | PDCoV & SADS-CoV (1:1) | ≥40 | ≥40 | 16.936 | 27.144 | 32.941 |
| Sample #11 | PEDV & TGEV & PDCoV (1:1:1) | 18.434 | 15.574 | 17.216 | ≥40 | 33.345 |
| Sample #12 | PEDV & TGEV & SADS-CoV (1:1:1) | 17.539 | 16.991 | ≥40 | 26.980 | 32.119 |
| Sample #13 | PEDV & PDCoV & SADS-CoV (1:1:1) | 17.215 | ≥40 | 17.22 | 27.434 | 32.812 |
| Sample #14 | TGEV & PDCoV & SADS-CoV (1:1:1) | ≥40 | 16.454 | 18.261 | 27.469 | 32.630 |
| Sample #15 | PEDV & TGEV & PDCoV & SADS-CoV (1:1:1:1) | 19.124 | 16.782 | 17.869 | 28.350 | 35.304 |
| Sample #16 | Nuclease-free water without XIPC | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
Notes: For samples #5–#15, the respective viruses were manually mixed at the equal volume ratio; the PEDV probe was labeled with fluorescence dye JUN; the TGEV probe was labeled with fluorescence dye VIC; the PDCoV probe was labeled with fluorescence dye ABY; the SADS-CoV probe was labeled with fluorescence dye FAM; XIPC is an internal positive control and its probe was labeled with fluorescence dye CY5.
Figure 1Amplification plots of 16 samples tested by the PEDV/PDCoV/TGEV/SADS-CoV/XIPC 5-plex PCR. The amplification curves corresponding to each fluorescence dye (JUN, VIC, ABY, FAM, and Cy5) are labeled accordingly. The identities of the samples #1–#16 are denoted in Table 4.
Analytical sensitivity of PEDV/PDCoV/TGEV/SADS-CoV/XIPC 5-plex PCR and the reference PEDV/TGEV/PDCoV PCR by testing serial dilutions of virus isolates.
| Dilution | PEDV Isolate IN19338/2013 | TGEV Purdue Isolate (VR-763) | PDCoV Isolate (USA/IL/2014) | |||
|---|---|---|---|---|---|---|
| 5-Plex PCR Ct Value | Reference PCR Ct Value | 5-Plex PCR Ct Value | Reference PCR Ct Value | 5-Plex PCR Ct Value | Reference PCR Ct Value | |
| 10−1 | 21.09 | 21.74 | 21.24 | 21.32 | 20.19 | 21.98 |
| 10−1 | 20.78 | 21.74 | 21.35 | 21.52 | 20.19 | 22.27 |
| 10−1 | 20.79 | 21.75 | 21.22 | 21.49 | 20.29 | 21.79 |
| 10−2 | 24.41 | 25.12 | 25.05 | 25.22 | 23.99 | 25.96 |
| 10−2 | 24.55 | 25.16 | 25.02 | 24.83 | 23.86 | 26.05 |
| 10−2 | 24.01 | 25.27 | 25.08 | 25.16 | 23.98 | 25.96 |
| 10−3 | 27.85 | 28.71 | 28.57 | 29.32 | 27.45 | 29.65 |
| 10−3 | 27.32 | 29.01 | 28.98 | 29.24 | 27.02 | 29.45 |
| 10−3 | 27.09 | 28.88 | 28.71 | 29.01 | 26.98 | 29.62 |
| 10−4 | 30.50 | 32.05 | 31.99 | 33.05 | 30.97 | 32.99 |
| 10−4 | 30.31 | 32.09 | 32.34 | 32.44 | 30.38 | 32.73 |
| 10−4 | 29.58 | 32.01 | 32.41 | 32.35 | 30.15 | 32.65 |
| 10−5 | 35.86 | 35.92 | 35.15 | 35.68 | 34.19 | 35.51 |
| 10−5 | 36.29 | 37.51 | 36.06 | 35.09 | 33.88 | 35.89 |
| 10−5 | 35.79 | 36.48 | 35.45 | 36.32 | 32.96 | 36.96 |
| 10−6 | ≥40 | 38.56 | ≥40 | 38.54 | 37.89 | ≥40 |
| 10−6 | ≥40 | 38.57 | 37.29 | 38.27 | 36.57 | ≥40 |
| 10−6 | 36.59 | 39.56 | ≥40 | 38.53 | 37.21 | 39.38 |
| 10−7 | ≥40 | ≥40 | ≥40 | ≥40 | 38.51 | ≥40 |
| 10−7 | ≥40 | 39.61 | 38.63 | ≥40 | ≥40 | 39.11 |
| 10−7 | ≥40 | ≥40 | ≥40 | ≥40 | 37.57 | ≥40 |
Limit of detection of PEDV/PDCoV/TGEV/SADS-CoV/XIPC 5-plex PCR by testing serial dilutions of IVT RNAs.
| Genomic Copies per Reaction | PEDV/PDCoV/TGEV/SADS-CoV/XIPC 5-Plex PCR * | |
|---|---|---|
|
| % (No. of Pos for PEDV) | Mean Ct (range) |
| 8 × 103 | 100% (3/3) | 24.28 (24.24–24.33) |
| 8 × 102 | 100% (3/3) | 27.71 (27.63–27.79) |
| 8 × 101 | 100% (20/20) | 31.35 (30.85–32.26) |
| 16 | 100% (20/20) | 33.76 (32.72–35.04) |
| 8 | 100% (20/20) | 34.55 (33.36–35.80) |
| 4 | 80% (16/20) | 35.7 (34.31–38.05) |
| 2 | 45% (9/20) | 37.53 (35.27–40) |
| 1 | 5% (1/20) | 38.70 (36.85–40) |
|
| % (No. of Pos for PDCoV) | Mean Ct (range) |
| 8 × 103 | 100% (3/3) | 24.02 (23.96–24.11) |
| 8 × 102 | 100% (3/3) | 27.64 (27.56–27.72) |
| 8 × 101 | 100% (3/3) | 31.41 (31.15–31.64) |
| 16 | 100% (20/20) | 33.95 (33.40–34.62) |
| 8 | 100% (20/20) | 34.93 (34.09–36.46) |
| 4 | 95% (19/20) | 36.24 (34.59–37.77) |
| 2 | 15% (3/20) | 37.92 (36.61–40) |
| 1 | 0% (0/20) | 38.71 (36.95–40) |
|
| % (No. of Pos for TGEV) | Mean Ct (range) |
| 8 × 103 | 100% (3/3) | 25.28 (25.21–25.34) |
| 8 × 102 | 100% (3/3) | 28.81 (28.75–28.85) |
| 8 × 101 | 100% (3/3) | 32.71 (32.67–32.77) |
| 16 | 95% (19/20) | 35.75 (34.83–37.34) |
| 8 | 25% (5/20) | 37.47 (35.87–38.75) |
| 4 | 0% (0/20) | 39.16 (37.14–40) |
| 2 | 0% (0/20) | 39.79 (37.95–40) |
| 1 | 0% (0/20) | 39.96 (39.61–40) |
|
| % (No. of Pos for SADS-CoV) | Mean Ct (range) |
| 1.36 × 104 | 100% (3/3) | 23.87 (23.84–23.90) |
| 1.36 × 103 | 100% (3/3) | 27.27 (27.15–27.35) |
| 1.36 × 102 | 100% (3/3) | 30.65 (30.54–30.75) |
| 27.2 | 100% (20/20) | 32.91 (32.35–34.58) |
| 13.6 | 100% (20/20) | 34.23 (33.54–35.21) |
| 6.8 | 100% (20/20) | 35.41 (34.53–36.76) |
| 3.4 | 85% (17/20) | 36.38 (35.25–38.55) |
| 1.7 | 35% (7/20) | 37.93 (35.94–40) |
* The PEDV/PDCoV/TGEV/SADS-CoV/XIPC 5-plex PCR Ct < 37 was considered positive for each virus.
Repeatability of PEDV/PDCoV/TGEV/SADS-CoV/XIPC 5-plex PCR by testing serial dilutions of in vitro transcribed RNA.
|
| Intra-Assay (3 Replicates for Each Dilution) | Inter-Assay (3 Plates for Each Dilution) | ||
|---|---|---|---|---|
| Mean Ct Value | CV, % | Mean Ct Value | CV, % | |
| 8.0 × 106 | 14.82 | 1.05 | 14.90 | 0.68 |
| 8.0 × 105 | 18.22 | 0.81 | 18.21 | 0.15 |
| 8.0 × 104 | 21.28 | 0.83 | 21.16 | 0.76 |
| 8.0 × 103 | 24.87 | 0.80 | 24.88 | 0.85 |
| 8.0 × 102 | 28.12 | 0.42 | 28.31 | 1.35 |
| 8.0 × 101 | 31.50 | 0.35 | 31.51 | 0.78 |
| 8.0 × 100 | 35.93 | 1.38 | 35.73 | 0.78 |
| Average intra-assay CV, % | 0.81 | Average inter-assay CV, % | 0.76 | |
|
| Intra-Assay (3 Replicates for Each Dilution) | Inter-Assay (3 plates for Each Dilution) | ||
| Mean Ct Value | CV, % | Mean Ct Value | CV, % | |
| 8.0 × 106 | 14.82 | 0.49 | 15.18 | 2.09 |
| 8.0 × 105 | 18.24 | 0.16 | 18.53 | 1.45 |
| 8.0 × 104 | 22.31 | 0.13 | 22.64 | 1.28 |
| 8.0 × 103 | 24.58 | 0.68 | 24.65 | 0.26 |
| 8.0 × 102 | 28.52 | 0.55 | 28.69 | 0.51 |
| 8.0 × 101 | 32.67 | 0.24 | 33.11 | 1.16 |
| 8.0 × 100 | 35.90 | 1.56 | 36.41 | 1.37 |
| Average intra-assay CV, % | 0.54 | Average inter-assay CV, % | 1.16 | |
|
| Intra-Assay (3 Replicates for Each Dilution) | Inter-assay (3 plates for each dilution) | ||
| Mean Ct Value | CV, % | Mean Ct Value | CV, % | |
| 8.0 × 106 | 15.39 | 0.10 | 15.43 | 0.23 |
| 8.0 × 105 | 18.92 | 0.36 | 19.09 | 0.78 |
| 8.0 × 104 | 22.92 | 0.22 | 23.01 | 0.37 |
| 8.0 × 103 | 25.57 | 0.16 | 25.59 | 0.27 |
| 8.0 × 102 | 29.50 | 0.09 | 29.85 | 1.13 |
| 8.0 × 101 | 33.51 | 0.67 | 33.77 | 0.86 |
| 8.0 × 100 | 37.90 | 3.01 | 37.67 | 1.13 |
| Average intra-assay CV, % | 0.66 | Average inter-assay CV, % | 0.68 | |
|
| Intra-Assay (3 Replicates for Each Dilution) | Inter-Assay (3 Plates for Each Dilution) | ||
| Mean Ct Value | CV, % | Mean Ct Value | CV, % | |
| 1.36 × 107 | 14.50 | 0.39 | 14.49 | 0.13 |
| 1.36 × 106 | 17.81 | 1.10 | 17.57 | 1.37 |
| 1.36 × 105 | 21.77 | 0.35 | 21.43 | 1.41 |
| 1.36 × 104 | 24.76 | 0.69 | 24.59 | 0.68 |
| 1.36 × 103 | 28.57 | 0.89 | 28.31 | 0.88 |
| 1.36 × 102 | 31.92 | 0.83 | 32.06 | 1.09 |
| 1.36 × 101 | 35.30 | 1.32 | 35.54 | 0.90 |
| Average intra-assay CV, % | 0.80 | Average inter-assay CV, % | 0.92 | |
Specimen types of 219 clinical samples and Ct ranges of positive samples tested by the reference PEDV/PDCoV/TGEV PCR.
| Specimen Type | Number | Reference PCR—PEDV Positive (Ct < 36) | Reference PCR—PDCoV Positive (Ct < 36) | Reference PCR—TGEV Positive (Ct < 36) | |||
|---|---|---|---|---|---|---|---|
| Number | Ct Range | Number | Ct range | Number | Ct range | ||
| Fecal swab | 54 | 21 | 16.6–33.2 | 13 | 15.5–35.7 | 3 | 25.4–31.1 |
| Feces | 53 | 20 | 14.5–30.2 | 32 | 14.1–36 | 9 | 14.9–28.4 |
| Oral fluid | 82 | 33 | 17.8–36 | 36 | 17.8–36 | 0 | |
| Small intestine | 30 | 22 | 15.2–35.2 | 1 | 20.7 | 0 | |
| Total | 219 | 96 | 82 | 12 | |||
Diagnostic performance of PEDV/PDCoV/TGEV/SADS-CoV/XIPC 5-plex PCR in comparison with the reference PEDV/TGEV/PDCoV PCR on clinical samples *.
| Reference PCR—PEDV | ||||
|---|---|---|---|---|
| Positive | Negative | Total | ||
| 5-plex PCR—PEDV | Positive | 95 | 6 | 101 |
| Negative | 1 | 117 | 118 | |
| Total | 96 | 123 | 219 | |
| Sensitivity 98.96%; specificity 95.12%; agreement 96.80% | ||||
|
| ||||
| Positive | Negative | Total | ||
| 5-plex PCR—PDCoV | Positive | 82 | 3 | 85 |
| Negative | 0 | 134 | 134 | |
| Total | 82 | 137 | 219 | |
| Sensitivity 100%; specificity 97.81%; agreement 98.63% | ||||
|
| ||||
| Positive | Negative | Total | ||
| 5-plex PCR—TGEV | Positive | 12 | 0 | 12 |
| Negative | 0 | 207 | 207 | |
| Total | 12 | 207 | 219 | |
| Sensitivity 100%; specificity 100%; agreement 100% | ||||
* Ct < 37 was considered positive for the PEDV/PDCoV/TGEV/SADS-CoV/XIPC 5-plex and Ct < 36 was considered positive for the reference PEDV/TGEV/PDCoV PCR.
Discrepancies on clinical samples between the PEDV/PDCoV/TGEV/SADS-CoV/XIPC 5-plex PCR and the reference PEDV/TGEV/PDCoV PCR *.
| Sample ID | Specimen | Reference PCR | 5-Plex PCR | |||||
|---|---|---|---|---|---|---|---|---|
| PEDV | PDCoV | TGEV | PEDV | PDCoV | TGEV | SADS-CoV | ||
| Sample_#23 | Fecal swab | 36.4 | ≥40 | ≥40 | 36.6 | ≥40 | ≥40 | ≥40 |
| Sample_#24 | Fecal swab | 36.4 | ≥40 | ≥40 | 35.1 | ≥40 | ≥40 | ≥40 |
| Sample_#27 | Fecal swab | 39.4 | ≥40 | ≥40 | 36.4 | ≥40 | ≥40 | ≥40 |
| Sample_#75 | Feces | 36.3 | 34.6 | ≥40 | 35.4 | 31.4 | ≥40 | ≥40 |
| Sample_#138 | Oral fluid | 35.0 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 | ≥40 |
| Sample_#144 | Oral fluid | 38.5 | ≥40 | ≥40 | 35.6 | ≥40 | ≥40 | ≥40 |
| Sample_#154 | Oral fluid | ≥40 | 28.6 | ≥40 | 35.8 | 27.4 | ≥40 | ≥40 |
| Sample_#113 | Oral fluid | 21.5 | 37.0 | ≥40 | 20.2 | 33.5 | ≥40 | ≥40 |
| Sample_#115 | Oral fluid | 24.6 | 36.8 | ≥40 | 23.8 | 36.4 | ≥40 | ≥40 |
| Sample_#145 | Oral fluid | 39.0 | 37.7 | ≥40 | 39.2 | 36.0 | ≥40 | ≥40 |
* Ct < 37 was considered positive for the PEDV/PDCoV/TGEV/SADS-CoV/XIPC 5-plex and Ct < 36 was considered positive for the reference PEDV/TGEV/PDCoV PCR.